News MSD rumoured to be eyeing $3bn+ MoonLake takeover Faced with the looming loss of patent protection for Keytruda, MSD is reported to be interested in buying Swiss immunology player MoonLake.
Views & Analysis Inside MoonLake’s raid on Merck KGaA’s inflammatory disease ... Swiss biotech MoonLake Immunotherapeutics has emerged with what it hopes is one of the hottest drugs in inflammatory diseases, sonelokimab.
News MoonLake launches, licensing in Merck KGaA's Cosentyx challe... There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KG
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
